Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Extensively Hydrolyzed Formula: Hypoallergenicity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01278446
Recruitment Status : Completed
First Posted : January 17, 2011
Last Update Posted : November 3, 2013
Information provided by (Responsible Party):

Brief Summary:
The primary objective of this clinical trial is to determine whether a new extensively hydrolyzed infant formula is hypoallergenic.

Condition or disease Intervention/treatment Phase
Food Hypersensitivity Other: Extensively hydrolyzed, whey protein infant formula Other: Extensively hydrolyzed, casein protein infant formula Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Evaluation of Hypoallergenicity of a 100% Whey, Extensively Hydrolyzed Infant Formula
Study Start Date : February 2011
Actual Primary Completion Date : June 2012
Actual Study Completion Date : August 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Casein

Arm Intervention/treatment
Experimental: Test Formula
New hydrolyzed whey formula
Other: Extensively hydrolyzed, whey protein infant formula
New hydrolyzed formula
Other Name: Baby Formula

Active Comparator: Control Formula
Commercially available hydrolyzed infant formula
Other: Extensively hydrolyzed, casein protein infant formula
Commercially available hydrolyzed infant formula
Other Name: Baby Formula

Primary Outcome Measures :
  1. Hypoallergenicity [ Time Frame: 14 Days ]
    To demonstrate that the test formula does not provoke allergenic activity

Secondary Outcome Measures :
  1. Digestive Tolerance [ Time Frame: 1 Week ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Months to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Born at term (>36 weeks gestation)
  2. Two (2) months to ≤ 12 years of age at enrollment
  3. Documented Cow's Milk Allergy (CMA) within the 6 months prior to enrollment by:

    1. Reported convincing allergic symptoms following an exposure to milk or a milk-containing food product and [detectable serum milk-specific IgE (>0.7 kIU/L) or positive skin prick test (wheal greater than 5 mm]), OR
    2. Physician-supervised oral food challenge that elicited immediate allergic symptoms, OR
    3. Results of laboratory tests highly predictive of clinical reactivity to milk

      • Serum milk IgE ≥15 [kIU/L]or ≥ 5 [kIU/L if younger than 1 year OR,
      • Skin prick tests mean wheal >10 mm
  4. Otherwise healthy
  5. If subject has asthma, atopic dermatitis, and/or rhinitis, must be well controlled
  6. Expected daily intake of at least 8 oz (240 ml) of the study formula during the open challenge phase
  7. Having obtained his/her legal representative's informed consent.

Exclusion Criteria:

  1. Children consuming mother's milk at the time of inclusion and during the trial
  2. Any chromosomal or major congenital anomalies
  3. Any major gastrointestinal disease or abnormalities other than CMA
  4. Chronic medical diseases (ie seizure disorders, chronic lung disease, heart problems (heart murmurs acceptable)
  5. Immunodeficiency
  6. Receiving free amino acid formula
  7. Anti-histamine use in 7 days prior to the first food challenge (eyedrops are acceptable)
  8. Oral steroid use within 14 days prior to enrollment (intranasal and topical corticosteroids are okay)
  9. Unstable asthma
  10. Severe uncontrolled eczema
  11. Recent ( within the last 3 months) severe anaphylactic reaction to milk
  12. Subject who in the Investigator's assessment cannot be expected to adhere to the study protocol
  13. Currently participating in another clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01278446

Layout table for location information
United States, Arkansas
Little Rock Allergy & Asthma
Little Rock, Arkansas, United States
United States, California
Pediatric Care Medical Group, Inc
Huntington Beach, California, United States
Allergy Medical Group of the North Area
Roseville, California, United States, 95678
United States, Georgia
Brookstone Clinical Research Center
Columbus, Georgia, United States
Aeroallergy Research Labs of Savannah
Savannah, Georgia, United States, 31406
United States, Idaho
Idaho Allergy and Asthma Specialists
Eagle, Idaho, United States, 83616
United States, Indiana
Deaconness Clinic
Evansville, Indiana, United States
United States, New Jersey
Anderson & Collins Clinical Research
Edison, New Jersey, United States
United States, New York
Mount Sinai Faculty Practice Associates Pediatric Allergy
New York, New York, United States, 10029
ENT & Allergy Associates
Newburgh, New York, United States
United States, North Carolina
Allergy Partners of Western North Carolina
Asheville, North Carolina, United States, 28801
United States, Texas
TTS Research
Boerne, Texas, United States
United States, Virginia
Clinical Research Partners
Henrico, Virginia, United States
Advanced Pediatrics
Vienna, Virginia, United States
Sponsors and Collaborators
Layout table for investigator information
Study Director: Jose Saavedra, MD Nestle Nutrition
Principal Investigator: Anna Nowak-Wegrzyn, MD Mount Sinai Department of Pediatrics
Layout table for additonal information
Responsible Party: Nestlé Identifier: NCT01278446    
Other Study ID Numbers: 09.42.PED
First Posted: January 17, 2011    Key Record Dates
Last Update Posted: November 3, 2013
Last Verified: November 2013
Keywords provided by Nestlé:
Cow's Milk Allergy
Additional relevant MeSH terms:
Layout table for MeSH terms
Food Hypersensitivity
Immune System Diseases
Hypersensitivity, Immediate
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action